2026-04-13T13:15:56Zhttps://recercat.cat/oai/request
oai:recercat.cat:2445/2228372025-12-05T00:02:17Zcom_2072_1057col_2072_478916col_2072_478917
RECERCAT author Liz, Joao Carlos Batista author Calvo Río, Vanesa author Sebastián Mora-Gil, María author Leonardo, María Teresa author Cristina Peñalba, Ana author Martín Penagos, Luis author Narváez, Javier author Sevilla Pérez, Belén author Callejas Rubio, José Luis author Gabrie, Ligia author Gálvez Sánchez, Rafael author Caminal Montero, Luis author Collado, Paz author Rodríguez Valls, María José author Argila, Diego de author Quiroga Colina, Patricia author Vicente Rbaneda, Esther Francisca author Rubio, Esteban author León Luque, Manuel author Blanco Madrigal, Juan María author Galíndez Agirregoikoa, Eva author Blanco, Ricardo author Pulito Cueto, Verónica author López Mejías, Raquel 2025-08-29T11:26:59Z2025-08-29T11:26:59Z2025-07-272025-08-26T09:51:06Z BackgroundIgA-mediated vasculitis (IgAV) is a complex inflammatory disease. Unravelling its genetic background would allow us to identify genetic biomarkers that may be used as additional tools in its daily management, helping to solve the clinical challenge that this vasculitis entails. C5 is a potent immune mediator that is proteolytically processed to generate C5a, a potent anaphylatoxin that exerts its function via C5aR1. C5 downstream variants (rs3761847 and rs10818488) have been recently related to IgAV pathogenesis. Additionally, C5a and C5aR1 dysregulation contributes to the development of inflammatory diseases, and, particularly, elevated C5a plasma levels have been observed in IgAV patients in the acute stage. Accordingly, we aimed to evaluate the influence of C5 and C5AR1 on the pathophysiology of IgAV.MethodsEight C5 (rs10760128, rs74971050, rs4310279, rs7868761, rs10818495, rs10156396, rs3815467, and rs16910280) and three C5AR1 (rs10853784, rs11673071, and rs11670789) tag variants were genotyped in 342 Caucasian IgAV patients and 723 ethnically matched healthy controls.ResultsNo statistically significant differences were observed when C5 and C5AR1 frequencies were compared between IgAV patients and healthy controls. Likewise, similar C5 and C5AR1 frequencies were observed amongst IgAV patients stratified according to IgAV severity (presence/absence of nephritis). Furthermore, no C5 and C5AR1 differences were disclosed when IgAV patients were stratified according to demographic and clinical IgAV characteristics other than nephritis (age at disease onset, presence/absence of joint and gastrointestinal manifestations) and sex.ConclusionsOur results suggest that C5 and C5AR1 are not related to IgAV pathogenesis and, therefore, these genes may not be useful as IgAV genetic biomarkers. cc by (c) Batista Liz, Joao Carlos et al, 2024 http://creativecommons.org/licenses/by/3.0/es/ info:eu-repo/semantics/openAccess Immunoglobulines Vasculitis Immunoglobulins Vasculitis Evaluating the usefulness of C5 and C5AR1 as genetic biomarkers of IgA-mediated vasculitis info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion